Overview of phase II trials of MTA in solid tumors
| Autor: | P J, O'Dwyer, K, Nelson, D E, Thornton |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
Antimetabolites Antineoplastic Guanine Lung Neoplasms Genital Neoplasms Female Breast Neoplasms Pemetrexed Thymidylate Synthase Clinical Trials Phase II as Topic Glutamates Head and Neck Neoplasms Carcinoma Non-Small-Cell Lung Neoplasms Folic Acid Antagonists Humans Female Enzyme Inhibitors Urogenital Neoplasms Gastrointestinal Neoplasms |
| Zdroj: | Seminars in oncology. 26(2 Suppl 6) |
| ISSN: | 0093-7754 |
| Popis: | MTA (LY231514, multitargeted antifolate) represents a new class of folate antimetabolites and inhibits multiple enzymes in the purine and thymidine biosynthetic pathways, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase. Based on the results of phase I investigation, the dose and schedule of 600 mg/m2 administered intravenously every 21 days was selected to carry into the phase II setting. A number of phase II studies are completed or ongoing in a wide range of tumor types, and encouraging results have been observed in colorectal, breast, non-small cell lung, head and neck, bladder, and cervical cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|